Clinical Evaluation of the ReLeaf Analgesic Infusion Catheter & Wound Drain

Sponsor
Vital 5, LLC (Industry)
Overall Status
Withdrawn
CT.gov ID
NCT02293525
Collaborator
(none)
0
2

Study Details

Study Description

Brief Summary

The purpose of this study is to evaluate the clinical performance of the ReLeaf infusion catheter & wound drain in patients following lumbar spinal fusion surgery. One half of the patients will receive continuous local analgesic fusion during the post-operative period while the other half will received continuous local saline.

Condition or Disease Intervention/Treatment Phase
N/A

Detailed Description

Posterior lumbar spinal fusion is commonly used in the management of a wide array of spinal disorders ranging from instability to degenerative disc disease. However, severe postoperative pain is a significant adverse outcome in patients who have undergone a lumbar spinal fusion procedure. This pain may delay mobilization and decrease compliance with physical, occupational, or pulmonary physiotherapy.

Pain symptoms may worsen with activity and ambulation due to reflex spasms of the paraspinal muscles elicited by pain from the wound. A local anesthetic agent administered immediately after surgery into the tissue surrounding the wound addresses the pain source for less than four hours. Therefore, it is reasonable to consider continuous local anesthetic infusion, which may limit local pain mediators for a longer duration.

Continuous local anesthetic infusion into the paraspinal musculature with the ReLeaf catheter has the potential to reduce pain, narcotic demand & usage, and accelerate the rate of recovery in lumbar spinal fusion patients.

Study Design

Study Type:
Interventional
Actual Enrollment :
0 participants
Allocation:
Randomized
Intervention Model:
Single Group Assignment
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose:
Supportive Care
Official Title:
Investigational Plan for the Clinical Evaluation of the ReLeaf Analgesic Infusion Catheter & Wound Drain
Actual Primary Completion Date :
Jan 1, 2016
Actual Study Completion Date :
Jan 1, 2016

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Ropivacaine

Continuous 0.2% Ropivacaine infusion until catheter removal (typically 36 hours)

Device: ReLeaf catheter
Continuous infusion rate 10ml/hr (5ml/side)

Drug: Ropivacaine
Other Names:
  • Naropin
  • Drug: Morphine
    Patient-controlled analgesia (PCA) at 1mg every 6 minutes with a 4 hour lock out after 30mg

    Drug: Oxycodone
    10mg every 4-6 hours
    Other Names:
  • Oxycontin, Roxicodone, Oxecta
  • Placebo Comparator: Saline

    Continuous saline infusion until catheter removal (typically 36 hours)

    Device: ReLeaf catheter
    Continuous infusion rate 10ml/hr (5ml/side)

    Drug: Saline

    Drug: Morphine
    Patient-controlled analgesia (PCA) at 1mg every 6 minutes with a 4 hour lock out after 30mg

    Drug: Oxycodone
    10mg every 4-6 hours
    Other Names:
  • Oxycontin, Roxicodone, Oxecta
  • Outcome Measures

    Primary Outcome Measures

    1. Pain (Mean VAS pain score at 24 hours post-procedure) [24 hours]

      Mean VAS pain score at 24 hours post-procedure

    Secondary Outcome Measures

    1. Medication Use [3 months]

      Narcotic use from surgery through 3 months post-operative

    2. Adverse Events [3 months]

      Occurrence of adverse events through 3 months post-operative

    Other Outcome Measures

    1. Length of Hospital Stay [Discharge, on average 2 to 3 days]

      Time from surgery to hospital discharge, on average 2 to 3 days

    2. Incisional Pain [3 months]

      Pain at the site of the incision at 3 months post-operative

    3. Incidence of nausea and vomiting [Discharge, on average 2 to 3 days]

      Occurrence of nausea with or without vomiting and treatments from time of surgery through hospital discharge (which is 2-3 days on average)

    4. Time of Foley Catheter Removal [Discharge, on average 2 to 3 days]

      Time foley catheter was removed following surgery but no later than hospital discharge (which is 2-3 days on average)

    5. Time to First Ambulate [Discharge, on average 2 to 3 days]

      Time to walk following surgery but no later than hospital discharge (which is 2-3 days on average)

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 85 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Skeletally mature

    • Diagnosis of lumbar spine disease requiring an open, midline, instrumented posterolateral fusion with or without interbody support at one or two vertebral levels and laminectomy or laminotomy

    • Physically and mentally willing to comply with the study requirements

    • Signed the study informed consent

    Exclusion Criteria:
    • Lumbar spine disease requiring more than two levels of instrumentation

    • Any previous operative lumbar procedure, except discectomy or hemi-laminotomy performed a minimum of 2 years prior to current study surgery

    • Patients requiring iliac crest bone graft for the procedure

    • Intra-operative durotomy

    • Any duration of pre-operative morphine or morphine equivalent use exceeding 30 mg of morphine equivalents per day for longer than 3 months

    • Physically or mentally compromised (i.e., being currently treated for a psychiatric disorder, senile dementia, Alzheimer's disease, presence of alcohol or substance abuse)

    • Diagnosed with Severe Depression and on treatment

    • Active infection at the operative level or a symptomatic infection

    • Diagnosed systemic disease that would affect the subject's welfare or overall outcome of the research study (i.e. Paget's disease, renal osteodystrophy, Lupus etc)

    • Is pregnant or breast feeding

    • Has any active malignancy or spinal arthrodesis being performed for a tumor decompression

    • Has a known allergy to local analgesics

    • Pending litigation related to back pain or injury or Worker's Compensation

    Contacts and Locations

    Locations

    No locations specified.

    Sponsors and Collaborators

    • Vital 5, LLC

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Vital 5, LLC
    ClinicalTrials.gov Identifier:
    NCT02293525
    Other Study ID Numbers:
    • CLI-001-0201
    First Posted:
    Nov 18, 2014
    Last Update Posted:
    Jan 22, 2016
    Last Verified:
    Jan 1, 2016
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jan 22, 2016